Danish Marine and Shipping Stock News

Omeros Corporation recently announced a definitive asset purchase and license agreement granting Novo Nordisk exclusive global rights to develop and commercialize zaltenibart, an experimental antibody targeting rare blood and kidney disorders, in exchange for US$340 million upfront and potential total payments of up to US$2.1 billion plus tiered royalties. This deal marks Novo Nordisk's significant move to diversify its portfolio beyond diabetes and obesity by investing in promising...

In early October 2025, DSV A/S was named as a victim of a ransomware attack by a new hacking group called the Coinbase Cartel, which specifically targets logistics companies through data exfiltration and extortion tactics. This incident highlights the elevated and evolving cybersecurity risks facing global supply chain operators and the logistics industry as a whole. We will examine how these rising cybersecurity concerns, punctuated by the recent ransomware attack, may alter DSV's...

On October 9, 2025, Jyske Bank A/S raised its earnings guidance for the year, now expecting a net profit of DKK 4.9 billion–5.3 billion and earnings per share of DKK 77–84, compared to previous forecasts at the upper end of DKK 3.8 billion–4.6 billion and DKK 60–73 per share. This upward revision signals management's increased confidence in the company's financial outlook and may reflect stronger operating conditions or improved cost controls. We'll explore how Jyske Bank's raised profit...

A.P. Møller - Mærsk (CPSE:MAERSK B) has kicked off the second phase of its large-scale share buy-back program, targeting up to DKK 7.2 billion in repurchases through early February 2026. Such buy-backs often attract investors' attention because of their implications for capital allocation and earnings. See our latest analysis for A.P. Møller - Mærsk. Mærsk's decision to ramp up its buy-back program arrives after a year of strong total shareholder returns, with the stock delivering 37.4% over...

Amidst political turmoil in France and international trade tensions, European markets have experienced a downturn, with the pan-European STOXX Europe 600 Index ending 1.10% lower and major stock indexes losing ground. In this environment of uncertainty and profit-taking, identifying stocks that may be trading at a discount becomes crucial for investors seeking value opportunities.

When researching a stock for investment, what can tell us that the company is in decline? Typically, we'll see the...

Recent reports have surfaced about DSV (CPSE:DSV) being targeted by a new hacking group that is focused on logistics companies. The ransomware claim highlights ongoing cybersecurity challenges for firms in the supply chain sector. See our latest analysis for DSV. DSV’s latest news comes after a challenging period for shareholders. While the company recently presented at the Xeneta Summit in Barcelona, its share price return year-to-date stands at -16.08%, and the past year’s total shareholder...

Key Insights Significant control over FLSmidth by retail investors implies that the general public has more power to...

If you are standing at a crossroads with your Vestas Wind Systems stock, wondering whether it is time to buy, sell, or simply hold, you are not alone. The recent journey of Vestas shares has been anything but boring, keeping both cautious and confident investors on their toes. Over the past month, the stock has surged 10.2%, and its year-to-date return stands impressively at 23.3%. These figures paint a picture of growing optimism around Vestas, despite a somewhat muted 1.5% gain over the...

GN Store Nord A/S ( CPH:GN ), might not be a large cap stock, but it received a lot of attention from a substantial...

If you're eyeing A.P. Møller - Mærsk and asking yourself whether now is the right time to buy, sell or just hang tight, you are certainly not alone. While many stocks have been doing a bit of a dance recently, Mærsk has shown its share of interesting moves that should catch the attention of any investor. In the short term, the share price has dipped, dropping 1.4% over the last week and 6.8% in the past month. But zoom out, and it is a very different story. The stock has climbed an impressive...

If you're watching Novo Nordisk and wondering what your next move should be, you're not alone. With shares closing at 362.45, the stock has been a bit of a rollercoaster, down 3.5% over the last week, but still up 4.1% for the past month. Long-term investors will remember the massive 75.2% gain over five years, but recent trends haven't been friendly. Year-to-date, shares have slid 43.3%, and over the last year, they've dropped a staggering 53.5%. This shift reflects more than just short-term...

Vestas Wind Systems (CPSE:VWS) just shared news of a series of firm wind turbine orders, covering Germany, Italy, Denmark, and the United Kingdom. This steady stream of deals highlights the company’s momentum in Europe’s clean energy transition. See our latest analysis for Vestas Wind Systems. After a challenging period, Vestas Wind Systems' latest wave of turbine deals is helping to reignite optimism. This is reflected in a 13.2% 1-month share price return and a 21.5% gain over the past 90...

When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...

The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with...

Bavarian Nordic (CPSE:BAVA) shares have caught some attention lately as investors weigh recent performance against mixed financial results for the past year. The company's stock has seen a notable shift over the past month. See our latest analysis for Bavarian Nordic. Bavarian Nordic's share price has rebounded sharply in the last quarter, posting a 27.6% gain as investors reassess its risk profile and long-term prospects following a year marked by mixed financials. While short-term swings...

Sydbank (CPSE:SYDB) shares have picked up some fresh attention after recent trading moves, leaving investors weighing the current valuation. The bank’s stock has delivered steady gains over the past month and has shown even stronger performance so far this year. See our latest analysis for Sydbank. After a strong run this year, Sydbank’s latest 6.9% share price return over the past month adds to its momentum and signals that investor interest is building. Looking further out, the bank has...

Ringkjøbing Landbobank (CPSE:RILBA) has caught the attention of market watchers recently. The stock has posted a 19% gain so far this year, supported by stable revenue and net income growth. See our latest analysis for Ringkjøbing Landbobank. Momentum has clearly been building for Ringkjøbing Landbobank, with its share price up nearly 19% year-to-date and the one-year total shareholder return reaching an impressive 36%. That steady climb suggests investors see upside potential, not just...

Aktieselskabet Schouw (CPSE:SCHO) shares have shown calm movement despite lacking a major event this week. For investors, it is a chance to step back and consider recent results as well as long-term progress. See our latest analysis for Aktieselskabet Schouw. Aktieselskabet Schouw’s share price has enjoyed a steady climb this year, gaining 10.5% year-to-date. Looking further back, its 8.1% total shareholder return over the last year and an impressive 40% over three years suggest that momentum...

Zealand Pharma's (CPH:ZEAL) stock is up by a considerable 35% over the past three months. Given the company's...

Vestas Wind Systems recently announced a surge in firm wind turbine orders across Europe, including over 239 MW in Germany, 346 MW spanning Germany, Denmark, and the UK, and 94 MW in Italy, featuring its latest EnVentus platform technology and long-term service agreements. This rapid expansion in order intake underscores growing customer confidence in Vestas' advanced solutions and highlights robust momentum for renewable energy projects in key European markets. We’ll examine how these...

Thinking about whether to buy, hold, or sell Genmab? You are not alone. With biotech names like Genmab, the decision can feel tricky, especially with the stock’s recent rally. Over the past month, Genmab has surged 15.5%, contributing to a strong year-to-date return of 33.5%. The company’s one-year return is also up 27.4%, signaling investors are warming up to its long-term prospects. Yet, if you look back further, you will notice that Genmab shares are still lagging over three and five...

Tryg (CPSE:TRYG) posted a net profit margin of 11.8%, down from 12.1% a year ago, reflecting year-over-year margin compression. While earnings had averaged a healthy 14.1% annual growth rate over the last five years, the most recent full-year results marked a reversal with negative growth recorded. Looking ahead, analysts are forecasting 4.7% annual earnings growth, just ahead of Denmark’s 4% market pace. However, revenue growth is expected to lag the wider market at 2.9% compared to...

Novo Nordisk (CPSE:NOVO B) shares have seen mixed performance over the past month, with a moderate 7% gain. This contrasts with recent volatility across the pharmaceutical sector. Investors are weighing long-term company fundamentals as short-term sentiment fluctuates. See our latest analysis for Novo Nordisk. While Novo Nordisk’s share price has climbed 7% over the past month, it’s important to note the bigger picture: the stock is still down sharply year-to-date, with a 41% decline, and its...